The Relative Efficacy of Treatments in First-Line Management of Newly Diagnosed Chronic Myeloid Leukaemia: Systematic Literature Review and Indirect Comparison.

1. Sawyers CL. Chronic myeloid leukemia. N Engl J Med. 1999;340(17):1330-40. 2. Alam A, Hussain S, Lal A, Lee D, Kristensen J. Molecular response to tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML), the Experience at Tawam Hospital, Abudhabi, UAE. Blood. 2012 16 Nov;120 (21). 3. Baccarani M, Pileri S, Steegmann JL, Muller M, Soverini S, Dreyling M, et al. Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2012 Oct;23 Suppl 7:vii727. 4. Mealing S, Barcena L, Hawkins N, Clark J, Eaton V, Hirji I, et al. The relative efficacy of imatinib, dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia: a systematic review and network metaanalysis. Experimental Hematology & Oncology. 2013;2(5):doi:10.1186/2162-3619-2-5. 5. Baccarani M, Shah N, Kantarjian H, et al. Dasatinib compared to imatinib in patients with newly diagnosed chronic-phase chronic myelogenous leukemia (CML-CP): results from the randomised phase 3 DASISION trial. EHA 15th Congress. 2010:Abstract no. 0560. 6. Hochhaus A, Shah N, Cortes J, et al. Efficacy and safety of dasatinib compared with imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): minimum 24 month follow-up from the DASISION trial. Haematologica. 2011;96(s2):Abstract no. 1011. 7. Kantarjian HM, Shah NP, Cortes JE, Baccarani M, Agarwal MB, Undurraga MS, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012 Feb;119(5):1123-9. 8. Shankar S. Dasatinib v imatinib in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Dasision 3-year follow-up. Indian Journal of Hematology and Blood Transfusion. 2013 December;29 (4):305. 9. Cortes J, Hochhaus A, Kim D-W, et al. Four-Year (Yr) Follow-Up Of Patients (Pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) Receiving Dasatinib Or Imatinib: Efficacy Based On Early Response Blood. 2013;122(21):Abstract no. 653. 10. Radich JP, Kopecky KJ, Appelbaum FR, Kamel-Reid S, Stock W, Malnassy G, et al. A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood. 2012 08 Nov;120(19):3898-905. 11. Hochhaus A, Lobo C, Clark R, et al. Continued superiority of nilotinib vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTND beyond 1 year. . Haematologica. 2010;95(s2):Abstract no. 1113. 12. Hughes TP, Hochhaus A, Saglio G, Kim DW, Jootar S, Le Coutre PD, et al. ENESTnd update: Continued superiority of nilotinib versus imatinib in patients with newly diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP). Blood. 2010 19 Nov;116 (21). 13. Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. The Lancet Oncology. 2011 Sep;12(9):841-51. 14. Larson RA, Hochhaus A, Hughes TP, Clark RE, Etienne G, Kim DW, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia. 2012 Oct;26(10):2197-203. 15. Larson RA, Hochhaus A, Saglio G, Kim DW, Jootar S, Le Coutre PD, et al. Nilotinib versus imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 4-year (y) update. Journal of Clinical Oncology. 2013 20 May;1). 16. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. New England Journal of Medicine. 2010 Jun 17;362(24):2251-9. 17. Huang X, Wang J, Baccarani M, Jevtic S, Ortmann CE, Yuan Y, et al. Frontline nilotinib results in superior rates of molecular response versus imatinib in chinese patients with chronic myeloid leukemia in chronic phase (CMLCP): Enestchina 12-month primary analysis. Blood. 2013 21 Oct;122 (21). 18. Hjorth-Hansen H, Richter J, Stenke L, Ehrencrona H, Gjertsen BT, Gedde-Dahl IT, et al. Dasatinib treatment induces fast and deep responses in newly diagnosed chronic myeloid leukemia (CML) patients in chronic phase: Clinical results from a randomized phase 2 study (nordcml006). Blood. 2013 21 Oct;122 (21). 19. National Institute of Health and Care Excellence. Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia (part review of technology appraisal guidance 70). NICE technology appraisals TA251. Available at: https://www. nice.org.uk/guidance/TA251 [Last accessed 17/09/14]. 2012. 20. Signorovitch J, Ayyagari R, Reichmann WM, Wu EQ, Chen L. Major molecular response during the first year of dasatinib, imatinib or nilotinib treatment for newly diagnosed chronic myeloid leukemia: A network meta-analysis. Cancer Treatment Reviews. 2014 March;40(2):285-92. Citations screened: 467